13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
27 檔
47.7%
As reported in its official Q3 2025 Form 13F filing, Novo Holdings A/S's tracked investment portfolio stood at $1.7B with 27 total positions.
In Q3 2025, Novo Holdings A/S adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 9 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including VTI, BN, ASML) accounted for 47.7% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VTI | Vanguard Total Stock Mkt ETF | ETF-Other | 21.97% | — | — | |
| 2 | BN | Brookfield CORP | Stock-Financials | 10.30% | -2.78% | — | |
| 3 | ASML | ASML Holding N.V. | Stock-Tech | 9.10% | +0.81% | -12.06% | |
| 4 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 5.97% | -2.27% | -15.73% | |
| 5 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.59% | -1.03% | — | |
| 6 | CRM | Salesforce Inc | Stock-Tech | 5.04% | -2.37% | — | |
| 7 | ✓ | Merus N V | Stock-Other | 4.55% | — | — | |
| 8 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 4.36% | -1.69% | +4.84% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.31% | -0.89% | — | |
| 10 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.96% | -1.19% | -30.89% | |
| 11 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.86% | — | -11.11% | |
| 12 | PHVS | Pharvaris N.V. | Stock-Other | 2.81% | -1.20% | +1.45% | |
| 13 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 2.49% | — | -17.95% | |
| 14 | AVBP | Arrivent Biopharma Inc | Stock-Other | 2.31% | -0.60% | +3.74% | |
| 15 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.30% | -3.02% | EXIT | |
| 16 | PCVX | Vaxcyte Inc | Stock-Other | 2.13% | -1.35% | — | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.00% | -0.87% | — | |
| 18 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.88% | -1.12% | +31.52% | |
| 19 | INSM | Insmed Inc | Stock-Healthcare | 1.86% | +0.75% | NEW | |
| 20 | VALN | Valneva Se - Adr | Stock-Other | 1.84% | -0.54% | EXIT | |
| 21 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.46% | -0.59% | — | |
| 22 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.28% | -3.07% | EXIT | |
| 23 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.12% | -0.24% | — | |
| 24 | LNZA | Lanzatech Global Inc | Stock-Other | 0.25% | -0.15% | — | |
| 25 | MQ | Marqeta Inc-a | Stock-Other | 0.15% | +0.27% | — | |
| 26 | IOBTQ | Io Biotech Inc | Stock-Other | 0.06% | — | -25.10% | |
| 27 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.02% | — | -13.35% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | +2% | — | Trim |
| 2 | ZBIO | Zenas Biopharma Inc | +1.5% | -11.11% | Trim |
| 3 | CRNX | Crinetics Pharmaceuticals In | +1.1% | +4.84% | Add |
| 4 | BN | Brookfield CORP | +1% | — | Unchanged |
| 5 | VRDN | Viridian Therapeutics Inc | +1% | — | Add |
| 6 | MIRM | Mirum Pharmaceuticals Inc | +0.8% | -15.73% | Trim |
| 7 | PHVS | Pharvaris N.V. | +0.8% | +1.45% | Add |
| 8 | ASML | ASML Holding N.V. | +0.7% | -12.06% | Trim |
| 9 | FDMT | 4d Molecular Therapeutics In | +0.6% | — | Add |
| 10 | CLDX | Celldex Therapeutics Inc | +0.3% | — | Unchanged |
| 11 | VTI | Vanguard Total Stock Mkt ETF | +0.3% | — | Unchanged |
| 12 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 13 | DMRA | Damora Therapeutics Inc | — | -13.35% | Trim |
| 14 | IOBTQ | Io Biotech Inc | -0.2% | -25.10% | Trim |
| 15 | AVBP | Arrivent Biopharma Inc | -0.3% | +3.74% | Add |
| 16 | BMRN | Biomarin Pharmaceutical Inc | -0.3% | — | Add |
| 17 | PCVX | Vaxcyte Inc | -0.5% | — | Add |
| 18 | CRM | Salesforce Inc | -0.5% | — | Add |
| 19 | BABA | Alibaba Group Holding-sp Adr | -0.8% | -30.89% | Trim |
| 20 | RXRX | Recursion Pharmaceuticals-a | -1.4% | -17.95% | Trim |
| 21 | INSM | Insmed Inc | -2.4% | -70.59% | Trim |
| 22 | EWTX | Edgewise Therapeutics Inc | -3.4% | — | Unchanged |
| 23 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 24 | VALN | Valneva Se - Adr | — | NEW | New buy |
| 25 | BBOT | Bridgebio Oncology Therapeut | — | NEW | New buy |
| 26 | AM6 | Amicus Therapeutics Inc | — | EXIT | Sold out |
| 27 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
| 28 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 29 | CBLL | Ceribell Inc | — | EXIT | Sold out |
| 30 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 31 | RCKT | Rocket Pharmaceuticals Inc | — | EXIT | Sold out |
| 32 | LXEO | Lexeo Therapeutics Inc | — | EXIT | Sold out |
| 33 | LNZA | Lanzatech Global Inc | — | NEW | New buy |
| 34 | ✓ | Lanzatech Global Inc | — | EXIT | Sold out |
| 35 | KYTX | Kyverna Therapeutics Inc | — | EXIT | Sold out |
| 36 | ABCL | Abcellera Biologics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 27 disclosed positions in Q3 2025.
During Q3 2025, Novo Holdings A/S's top holdings by market value included VTI (22.0%)、BN (10.3%)、ASML (9.1%). The largest single position, VTI, represented 22.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ELVN
市值: $29.2M
Top Position Liquidated / Trimmed
AM6
前期市值: $22.4M
In Q3 2025, Novo Holdings A/S made 31 total portfolio adjustments, initiating 5 new buys, adding to 8 positions, trimming 9 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.